Accelerate to discover

Homepage>Discover>Assessment of CAR T Cell killing capacity against solid tumors-Thursday, October 20, 2016, 5 pm CEST

Sep 30, 2020

Extracellular vesicles (EVs) are lipid spheres released from cells. EVs express proteins and contain cargo that pertain...

IncuCyte webinar : clonal heterogeneity promotes metabolite exchange to support pancreatic tumor

Sep 25, 2020

Pancreatic ductaladenocarcinoma (PDA) is the third leading cause of cancer related death in the United States,...

Quantitative evaluation of pulmonary function with hyperpolarized xenon gas MR

Aug 20, 2020

Hyperpolarized 129Xe MR has been proven to be a powerful tool to evaluate the pulmonary function and has been widely...

Applications of Hyperpolarized 129Xe MRI for functional imaging of the lungs

Aug 11, 2020

2015 marked the first ever translation of hyperpolarized gas MRI to diagnostic clinical practice. Research at the...

Oct 22, 2020

Micro-CT: Fancy gadget or indispensable technology towards quantification of lung diseases?

Jul 29, 2020

Technology allowing evaluation of live animals repeatedly is indispensable to gain better insight into the dynamics of...

Breakthrough discoveries from shear flow assays for Platelet biology and vascular studies

Jul 17, 2020

After a short introduction on the physio-pathological roles of platelets and the importance of their cell adhesion...

Hybrid PET/MR enables exploration of new science

Jul 14, 2020

Watch the recorded webinar on PET/MR, driven by Peter Caravan at MGH for the application part, during which the launch...

Oct 22, 2020

IncuCyte webinar: Advances in 3D cell models for cancer biology

Jul 1, 2020

Get answers to your questions on 3D spheroid-based drug discovery, organoid research and working with advanced cell...

Show all topics (10)

Assessment of CAR T Cell killing capacity against solid tumors-Thursday, October 20, 2016, 5 pm CEST

Oct 13, 2016

Nabil Ahmed, M.D., M.P.H. Associate Professor of Pediatrics, Baylor College of Medicine (USA).

Robust CAR design and sensitive yet realistic functional testing will be required in order to improve the efficacy of CAR T cell therapies targeting solid tumors. We have used the xCELLigence Real-Time Cell Analyzer as a high-throughput platform to test multiple CAR components including extracellular domains (including bi-specifics), signaling endo-domains, as well as next-generation CAR T cell products that are inherently resistant to checkpoint blockade. This platform has proven very sensitive to subtle yet longitudinally meaningful differences in CAR design, and has made it possible to evaluate T cell products in a "stress test" that is more representative of early phase trial requirements.

Register now

Webinar

Related technologies: Real-time, label free cell analysis

Get more info